Europe Drug modeling software Market - Industry Trends and Forecast to 2030

List of Tables

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:

Europe Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User( Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country (Germany, France , U.K., Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium,Poland, Sweden, Denmark, Finland, Norway, Rest of Europe)- Industry Trends and Forecast to 2030.

Overview of Drug Modeling Software Market Dynamics :

Driver
Rising drug discovery and development activities
Restrain
Lack of quality data base
Opportunity
Cloud computing and big data analytics in drug modelling

Market Players:

The key market players operating in the drug modeling software market are listed below:

Dotmatics
BC Platforms
InSilicoTrials Technologies.
VeriSIM Life., Atomwise Inc.
Certara, USA.
GENECODE
Cresset., and Nanome Inc.
SIMULATIONS PLUS.
Dassault Systemes
Scripps Research
XtalPi Inc.
Xybion
ArgusLab
Schrodinger, Inc.

1 INTRODUCTION 57

1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE EUROPE DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59

2 MARKET SEGMENTATION 62

2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82

4 MARKET OVERVIEW 83

4.1 DRIVERS 85
- 4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
- 4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
- 4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
- 4.2.1 LACK OF QUALITY DATA BASE 89
- 4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
- 4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
- 4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
- 4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
- 4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92

5 EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93

5.1 OVERVIEW 94
- 5.1.1 SOFTWARE 97
  - 5.1.1.1 INTEGRATED 98
  - 5.1.1.2 STANDALONE 98
  - 5.1.1.3 LIGAND BASED 98
  - 5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
- 5.2.1 PROFESSIONAL SERVICES 99
  - 5.2.1.1 CONSULTING AND TRAINING 100
  - 5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
  - 5.2.1.3 SUPPORT AND MAINTENANCE 100
- 5.2.2 MANAGED SERVICES 100

6 EUROPE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101

6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107

7 EUROPE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108

7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113

8 EUROPE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114

8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118

9 EUROPE DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120

9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130

10 EUROPE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131

10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
- 10.2.1 ANNUALLY SUBSCRIPTION 136
- 10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
- 10.3.1 GROUP LICENSE 137
- 10.3.2 DESKTOP LICENSE 137
- 10.3.3 OTHERS 137

11 EUROPE DRUG MODELING SOFTWARE MARKET, BY END USER 138

11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
- 11.2.1 LARGE ENTERPRISE SIZE 143
- 11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
- 11.3.1 LARGE ENTERPRISE SIZE 144
- 11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
- 11.4.1 LARGE ENTERPRISE SIZE 145
- 11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
- 11.5.1 LARGE ENTERPRISE SIZE 146
- 11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
- 11.6.1 LARGE ENTERPRISE SIZE 148
- 11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148

12 EUROPE DRUG MODELING SOFTWARE MARKET, BY REGION 149

12.1 EUROPE 150
- 12.1.1 GERMANY 161
- 12.1.2 FRANCE 166
- 12.1.3 U.K. 171
- 12.1.4 ITALY 176
- 12.1.5 RUSSIA 181
- 12.1.6 SPAIN 186
- 12.1.7 TURKEY 191
- 12.1.8 NETHERLANDS 196
- 12.1.9 SWITZERLAND 201
- 12.1.10 BELGIUM 206
- 12.1.11 POLAND 211
- 12.1.12 SWEDEN 216
- 12.1.13 DENMARK 221
- 12.1.14 FINLAND 226
- 12.1.15 NORWAY 231
- 12.1.16 REST OF EUROPE 236

13 EUROPE DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 237

13.1 COMPANY SHARE ANALYSIS: EUROPE 237

14 SWOT ANALYSIS 238

15 EUROPE DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 239

15.1 DASSAULT SYSTEMES 239
- 15.1.1 COMPANY SNAPSHOT 239
- 15.1.2 REVENUE ANALYSIS 239
- 15.1.3 COMPANY SHARE ANALYSIS 240
- 15.1.4 PRODUCT PORTFOLIO 240
- 15.1.5 RECENT DEVELOPMENT 240
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 241
- 15.2.1 COMPANY SNAPSHOT 241
- 15.2.2 REVENUE ANALYSIS 241
- 15.2.3 COMPANY SHARE ANALYSIS 242
- 15.2.4 PRODUCT PORTFOLIO 242
- 15.2.5 RECENT DEVELOPMENTS 242
15.3 CERTARA, USA. 243
- 15.3.1 COMPANY SNAPSHOT 243
- 15.3.2 REVENUE ANALYSIS 243
- 15.3.3 COMPANY SHARE ANALYSIS 244
- 15.3.4 PRODUCT PORTFOLIO 244
- 15.3.5 RECENT DEVELOPMENTS 244
15.4 SCHRODINGER, INC. 245
- 15.4.1 COMPANY SNAPSHOT 245
- 15.4.2 REVENUE ANALYSIS 245
- 15.4.3 COMPANY SHARE ANALYSIS 246
- 15.4.4 PRODUCT PORTFOLIO 246
- 15.4.5 RECENT DEVELOPMENT 246
15.5 CRESSET. 247
- 15.5.1 COMPANY SNAPSHOT 247
- 15.5.2 COMPANY SHARE ANALYSIS 247
- 15.5.3 PRODUCT PORTFOLIO 248
- 15.5.4 RECENT DEVELOPMENTS 248
15.6 ACELLERA LTD 249
- 15.6.1 COMPANY SNAPSHOT 249
- 15.6.2 PRODUCT PORTFOLIO 249
- 15.6.3 RECENT DEVELOPMENTS 249
15.7 ARGUSLAB 250
- 15.7.1 COMPANY SNAPSHOT 250
- 15.7.2 PRODUCT PORTFOLIO 250
- 15.7.3 RECENT DEVELOPMENT 250
15.8 ATOMWISE INC. 251
- 15.8.1 COMPANY SNAPSHOT 251
- 15.8.2 PRODUCT PORTFOLIO 251
- 15.8.3 RECENT DEVELOPMENT 251
15.9 BC PLATFORMS 252
- 15.9.1 COMPANY SNAPSHOT 252
- 15.9.2 PRODUCT PORTFOLIO 252
- 15.9.3 RECENT DEVELOPMENTS 253
15.10 BIOSOLVEIT GMBH 254
- 15.10.1 COMPANY SNAPSHOT 254
- 15.10.2 PRODUCT PORTFOLIO 254
- 15.10.3 RECENT DEVELOPMENT 254
15.11 DOTMATICS 255
- 15.11.1 COMPANY SNAPSHOT 255
- 15.11.2 PRODUCT PORTFOLIO 255
- 15.11.3 RECENT DEVELOPMENTS 256
15.12 GENECODE 257
- 15.12.1 COMPANY SNAPSHOT 257
- 15.12.2 PRODUCT PORTFOLIO 257
- 15.12.3 RECENT DEVELOPMENT 257
15.13 INSILICOTRIALS TECHNOLOGIES. 258
- 15.13.1 COMPANY SNAPSHOT 258
- 15.13.2 PRODUCT PORTFOLIO 258
- 15.13.3 RECENT DEVELOPMENTS 259
15.14 NANOME INC. 260
- 15.14.1 COMPANY SNAPSHOT 260
- 15.14.2 PRODUCT PORTFOLIO 260
- 15.14.3 RECENT DEVELOPMENT 260
15.15 OPTIBRIUM, LTD. 261
- 15.15.1 COMPANY SNAPSHOT 261
- 15.15.2 PRODUCT PORTFOLIO 261
- 15.15.3 RECENT DEVELOPMENT 261
15.16 PHARMACELERA 262
- 15.16.1 COMPANY SNAPSHOT 262
- 15.16.2 PRODUCT PORTFOLIO 262
- 15.16.3 RECENT DEVELOPMENT 262
15.17 SIMULATIONS PLUS. 263
- 15.17.1 COMPANY SNAPSHOT 263
- 15.17.2 REVENUE ANALYSIS 264
- 15.17.3 COMPANY SHARE ANALYSIS 265
- 15.17.4 PRODUCT PORTFOLIO 265
- 15.17.5 RECENT DEVELOPMENT 266
15.18 THE SCRIPPS RESEARCH INSTITUTE 267
- 15.18.1 COMPANY SNAPSHOT 267
- 15.18.2 PRODUCT PORTFOLIO 267
- 15.18.3 RECENT DEVELOPMENT 267
15.19 VERISIM LIFE. 268
- 15.19.1 COMPANY SNAPSHOT 268
- 15.19.2 PRODUCT PORTFOLIO 268
- 15.19.3 RECENT DEVELOPMENTS 268
15.20 XTALPI INC. 269
- 15.20.1 COMPANY SNAPSHOT 269
- 15.20.2 PRODUCT PORTFOLIO 269
- 15.20.3 RECENT DEVELOPMENT 269
15.21 XYBION DIGITAL INC. 270
- 15.21.1 COMPANY SNAPSHOT 270
- 15.21.2 REVENUE ANALYSIS 270
- 15.21.3 PRODUCT PORTFOLIO 271
- 15.21.4 RECENT DEVELOPMENT 271

16 QUESTIONNAIRE 272

17 RELATED REPORTS 276

LIST OF TABLES

TABLE 1 EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 69
TABLE 2 EUROPE SOFTAWARE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 3 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 70
TABLE 4 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 71
TABLE 5 EUROPE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 6 EUROPE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 72
TABLE 7 EUROPE PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 73
TABLE 8 EUROPE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 77
TABLE 9 EUROPE WINDOWS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 10 EUROPE LINUX IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 11 EUROPE MAC OS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 12 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 13 EUROPE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 84
TABLE 14 EUROPE CLOUD BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 15 EUROPE HYBRID-BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 16 EUROPE ON-PREMISES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 17 EUROPE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 90
TABLE 18 EUROPE LARGE ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 19 EUROPE SMALL & MEDIUM ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 20 EUROPE DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 96
TABLE 21 EUROPE GRAPHICAL MOLECULAR MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 22 EUROPE GENE SEQUENCE ANALYSIS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 23 EUROPE PROTEIN MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 24 EUROPE MODELING CRYSTAL STRUCTURES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 25 EUROPE CHEMINFORMATICS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 26 EUROPE HIGH THROUGHPUT VIRTUAL SCREENING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 27 EUROPE GAS & SOLUTION PHASE REACTION IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 28 EUROPE MEDICAL IMAGING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 29 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 30 EUROPE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 107
TABLE 31 EUROPE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 32 EUROPE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 108
TABLE 33 EUROPE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 34 EUROPE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 110
TABLE 35 EUROPE DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 114
TABLE 36 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 37 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 115
TABLE 38 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 39 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 117
TABLE 40 EUROPE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 41 EUROPE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 118
TABLE 42 EUROPE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 43 EUROPE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 119
TABLE 44 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 45 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 120
TABLE 46 EUROPE DRUG MODELING SOFTWARE MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 128
TABLE 47 EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 128
TABLE 48 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 49 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 50 EUROPE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 51 EUROPE PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 52 EUROPE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 129
TABLE 53 EUROPE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 130
TABLE 54 EUROPE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 130
TABLE 55 EUROPE DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 130
TABLE 56 EUROPE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 131
TABLE 57 EUROPE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 131
TABLE 58 EUROPE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 131
TABLE 59 EUROPE DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 131
TABLE 60 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 132
TABLE 61 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 132
TABLE 62 EUROPE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 132
TABLE 63 EUROPE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 132
TABLE 64 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 133
TABLE 65 GERMANY DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 134
TABLE 66 GERMANY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 67 GERMANY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 68 GERMANY SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
TABLE 69 GERMANY PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
TABLE 70 GERMANY DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 135
TABLE 71 GERMANY DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 135
TABLE 72 GERMANY DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 135
TABLE 73 GERMANY DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 136
TABLE 74 GERMANY DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 136
TABLE 75 GERMANY SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 136
TABLE 76 GERMANY ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 137
TABLE 77 GERMANY DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 137
TABLE 78 GERMANY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 137
TABLE 79 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 137
TABLE 80 GERMANY RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 138
TABLE 81 GERMANY REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 138
TABLE 82 GERMANY OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 138
TABLE 83 FRANCE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 139
TABLE 84 FRANCE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 85 FRANCE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 139
TABLE 86 FRANCE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 139
TABLE 87 FRANCE PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 140
TABLE 88 FRANCE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 140
TABLE 89 FRANCE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 140
TABLE 90 FRANCE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 140
TABLE 91 FRANCE DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 141
TABLE 92 FRANCE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 141
TABLE 93 FRANCE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 141
TABLE 94 FRANCE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 142
TABLE 95 FRANCE DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 142
TABLE 96 FRANCE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 142
TABLE 97 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 142
TABLE 98 FRANCE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 143
TABLE 99 FRANCE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 143
TABLE 100 FRANCE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 143
TABLE 101 U.K. DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 144
TABLE 102 U.K. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 103 U.K. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 144
TABLE 104 U.K. SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 144
TABLE 105 U.K. PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
TABLE 106 U.K. DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 145
TABLE 107 U.K. DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 145
TABLE 108 U.K. DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 145
TABLE 109 U.K. DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 146
TABLE 110 U.K. DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 146
TABLE 111 U.K. SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 146
TABLE 112 U.K. ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 147
TABLE 113 U.K. DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 114 U.K. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 147
TABLE 115 U.K. CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 147
TABLE 116 U.K. RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 148
TABLE 117 U.K. REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 148
TABLE 118 U.K. OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 148
TABLE 119 ITALY DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 149
TABLE 120 ITALY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 149
TABLE 121 ITALY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
TABLE 122 ITALY SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
TABLE 123 ITALY PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 150
TABLE 124 ITALY DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 150
TABLE 125 ITALY DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 150
TABLE 126 ITALY DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 150
TABLE 127 ITALY DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 151
TABLE 128 ITALY DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 151
TABLE 129 ITALY SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 151
TABLE 130 ITALY ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 152
TABLE 131 ITALY DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 152
TABLE 132 ITALY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 152
TABLE 133 ITALY CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 152
TABLE 134 ITALY RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 153
TABLE 135 ITALY REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 153
TABLE 136 ITALY OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 153
TABLE 137 RUSSIA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 154
TABLE 138 RUSSIA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154
TABLE 139 RUSSIA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
TABLE 140 RUSSIA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
TABLE 141 RUSSIA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 155
TABLE 142 RUSSIA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 155
TABLE 143 RUSSIA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 155
TABLE 144 RUSSIA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 155
TABLE 145 RUSSIA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
TABLE 146 RUSSIA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 156
TABLE 147 RUSSIA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 156
TABLE 148 RUSSIA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 157
TABLE 149 RUSSIA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 157
TABLE 150 RUSSIA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 157
TABLE 151 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 157
TABLE 152 RUSSIA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 158
TABLE 153 RUSSIA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 158
TABLE 154 RUSSIA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 158
TABLE 155 SPAIN DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 159
TABLE 156 SPAIN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 157 SPAIN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 158 SPAIN SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 159 SPAIN PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 160
TABLE 160 SPAIN DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 160
TABLE 161 SPAIN DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 160
TABLE 162 SPAIN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 160
TABLE 163 SPAIN DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 161
TABLE 164 SPAIN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 161
TABLE 165 SPAIN SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 161
TABLE 166 SPAIN ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 162
TABLE 167 SPAIN DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 162
TABLE 168 SPAIN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 162
TABLE 169 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 162
TABLE 170 SPAIN RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 163
TABLE 171 SPAIN REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 163
TABLE 172 SPAIN OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 163
TABLE 173 TURKEY DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 164
TABLE 174 TURKEY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 175 TURKEY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
TABLE 176 TURKEY SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
TABLE 177 TURKEY PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
TABLE 178 TURKEY DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 165
TABLE 179 TURKEY DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 165
TABLE 180 TURKEY DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 165
TABLE 181 TURKEY DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
TABLE 182 TURKEY DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 166
TABLE 183 TURKEY SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 166
TABLE 184 TURKEY ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 167
TABLE 185 TURKEY DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 167
TABLE 186 TURKEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 167

TABLE 187 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 167
TABLE 188 TURKEY RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
TABLE 189 TURKEY REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
TABLE 190 TURKEY OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
TABLE 191 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 169
TABLE 192 NETHERLANDS SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
TABLE 193 NETHERLANDS SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
TABLE 194 NETHERLANDS SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
TABLE 195 NETHERLANDS PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
TABLE 196 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 170
TABLE 197 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 170
TABLE 198 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 170
TABLE 199 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
TABLE 200 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 171
TABLE 201 NETHERLANDS SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 171
TABLE 202 NETHERLANDS ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 172
TABLE 203 NETHERLANDS DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 172
TABLE 204 NETHERLANDS PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 172
TABLE 205 NETHERLANDS CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 172
TABLE 206 NETHERLANDS RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
TABLE 207 NETHERLANDS REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
TABLE 208 NETHERLANDS OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
TABLE 209 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 174
TABLE 210 SWITZERLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
TABLE 211 SWITZERLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
TABLE 212 SWITZERLAND SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
TABLE 213 SWITZERLAND PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
TABLE 214 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 175
TABLE 215 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 175
TABLE 216 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 175
TABLE 217 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
TABLE 218 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 176
TABLE 219 SWITZERLAND SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 176
TABLE 220 SWITZERLAND ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 177
TABLE 221 SWITZERLAND DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 177
TABLE 222 SWITZERLAND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 177
TABLE 223 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 177
TABLE 224 SWITZERLAND RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
TABLE 225 SWITZERLAND REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
TABLE 226 SWITZERLAND OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
TABLE 227 BELGIUM DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 179
TABLE 228 BELGIUM SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 179
TABLE 229 BELGIUM SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
TABLE 230 BELGIUM SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
TABLE 231 BELGIUM PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 180
TABLE 232 BELGIUM DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 180
TABLE 233 BELGIUM DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 180
TABLE 234 BELGIUM DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 180
TABLE 235 BELGIUM DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 181
TABLE 236 BELGIUM DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 181
TABLE 237 BELGIUM SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 181
TABLE 238 BELGIUM ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 182
TABLE 239 BELGIUM DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 182
TABLE 240 BELGIUM PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 182
TABLE 241 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 182
TABLE 242 BELGIUM RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
TABLE 243 BELGIUM REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
TABLE 244 BELGIUM OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
TABLE 245 POLAND DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 184
TABLE 246 POLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 184
TABLE 247 POLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 184
TABLE 248 POLAND SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 184
TABLE 249 POLAND PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 185
TABLE 250 POLAND DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 185
TABLE 251 POLAND DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 185
TABLE 252 POLAND DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 185
TABLE 253 POLAND DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 186
TABLE 254 POLAND DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 186
TABLE 255 POLAND SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 186
TABLE 256 POLAND ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 187
TABLE 257 POLAND DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 187
TABLE 258 POLAND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 187
TABLE 259 POLAND CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 187
TABLE 260 POLAND RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 188
TABLE 261 POLAND REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 188
TABLE 262 POLAND OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 188
TABLE 263 SWEDEN DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 189
TABLE 264 SWEDEN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 189
TABLE 265 SWEDEN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 189
TABLE 266 SWEDEN SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 189
TABLE 267 SWEDEN PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
TABLE 268 SWEDEN DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 190
TABLE 269 SWEDEN DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 190
TABLE 270 SWEDEN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 190
TABLE 271 SWEDEN DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 191
TABLE 272 SWEDEN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 191
TABLE 273 SWEDEN SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 191
TABLE 274 SWEDEN ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 192
TABLE 275 SWEDEN DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 192
TABLE 276 SWEDEN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 192
TABLE 277 SWEDEN CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 192
TABLE 278 SWEDEN RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
TABLE 279 SWEDEN REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
TABLE 280 SWEDEN OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
TABLE 281 DENMARK DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 194
TABLE 282 DENMARK SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 194
TABLE 283 DENMARK SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 284 DENMARK SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 194
TABLE 285 DENMARK PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
TABLE 286 DENMARK DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 195
TABLE 287 DENMARK DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 195
TABLE 288 DENMARK DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 195
TABLE 289 DENMARK DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 196
TABLE 290 DENMARK DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 196
TABLE 291 DENMARK SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 196
TABLE 292 DENMARK ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 197
TABLE 293 DENMARK DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 197
TABLE 294 DENMARK PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 197
TABLE 295 DENMARK CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 197
TABLE 296 DENMARK RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 198
TABLE 297 DENMARK REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 198
TABLE 298 DENMARK OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 198
TABLE 299 FINLAND DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 199
TABLE 300 FINLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 199
TABLE 301 FINLAND SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 302 FINLAND SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
TABLE 303 FINLAND PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
TABLE 304 FINLAND DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 200
TABLE 305 FINLAND DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 200
TABLE 306 FINLAND DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 200
TABLE 307 FINLAND DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 201
TABLE 308 FINLAND DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 201
TABLE 309 FINLAND SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 201
TABLE 310 FINLAND ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 202
TABLE 311 FINLAND DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 202
TABLE 312 FINLAND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 202
TABLE 313 FINLAND CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 202
TABLE 314 FINLAND RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 203
TABLE 315 FINLAND REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 203
TABLE 316 FINLAND OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 203
TABLE 317 NORWAY DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 204
TABLE 318 NORWAY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 204
TABLE 319 NORWAY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 204
TABLE 320 NORWAY SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 204
TABLE 321 NORWAY PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 205
TABLE 322 NORWAY DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 205
TABLE 323 NORWAY DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 205
TABLE 324 NORWAY DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 205
TABLE 325 NORWAY DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 206
TABLE 326 NORWAY DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 206
TABLE 327 NORWAY SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 206
TABLE 328 NORWAY ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 207
TABLE 329 NORWAY DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 207
TABLE 330 NORWAY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 207
TABLE 331 NORWAY CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 207
TABLE 332 NORWAY RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 208
TABLE 333 NORWAY REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 208
TABLE 334 NORWAY OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 208
TABLE 335 REST OF EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 209

LIST OF FIGURES

FIGURE 1 EUROPE DRUG MODELING SOFTWARE MARKET: SEGMENTATION 33
FIGURE 2 EUROPE DRUG MODELING SOFTWARE MARKET: DATA TRIANGULATION 36
FIGURE 3 EUROPE DRUG MODELING SOFTWARE MARKET: DROC ANALYSIS 37
FIGURE 4 EUROPE DRUG MODELING SOFTWARE MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS 38
FIGURE 5 EUROPE DRUG MODELING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS 38
FIGURE 6 EUROPE DRUG MODELING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS 39
FIGURE 7 EUROPE DRUG MODELING SOFTWARE MARKET: MULTIVARIATE MODELING 40
FIGURE 8 EUROPE DRUG MODELING SOFTWARE MARKET: DBMR MARKET POSITION GRID 41
FIGURE 9 EUROPE DRUG MODELING SOFTWARE MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 EUROPE DRUG MODELING SOFTWARE MARKET: MARKET APPLICATION COVERAGE GRID 43
FIGURE 11 EUROPE DRUG MODELING SOFTWARE MARKET: SEGMENTATION 47
FIGURE 12 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES, RISING DEMAND FOR NOVEL THERAPIES, AND PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING ARE ARE EXPECTED TO DRIVE THE EUROPE DRUG MODELING SOFTWARE MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030 48
FIGURE 13 SOFTWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DRUG MODELING SOFTWARE MARKET IN 2023 & 2030 48
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DRUG MODELING SOFTWARE MARKET 55
FIGURE 15 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2022 65
FIGURE 16 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2023-2030 (USD MILLION) 66
FIGURE 17 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, CAGR (2023-2030) 66
FIGURE 18 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, LIFELINE CURVE 67
FIGURE 19 EUROPE DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2022 73
FIGURE 20 EUROPE DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2023-2030 (USD MILLION) 74
FIGURE 21 EUROPE DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, CAGR (2023-2030) 74
FIGURE 22 EUROPE DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, LIFELINE CURVE 75
FIGURE 23 EUROPE DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2022 80
FIGURE 24 EUROPE DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2023-2030 (USD MILLION) 81
FIGURE 25 EUROPE DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, CAGR (2023-2030) 81
FIGURE 26 EUROPE DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, LIFELINE CURVE 82
FIGURE 27 EUROPE DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2022 86
FIGURE 28 EUROPE DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2023-2030 (USD MILLION) 87
FIGURE 29 EUROPE DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, CAGR (2023-2030) 87
FIGURE 30 EUROPE DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, LIFELINE CURVE 88
FIGURE 31 EUROPE DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2022 92
FIGURE 32 EUROPE DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 93
FIGURE 33 EUROPE DRUG MODELING SOFTWARE MARKET: BY APPLICATION, CAGR (2023-2030) 93
FIGURE 34 EUROPE DRUG MODELING SOFTWARE MARKET: BY APPLICATION, LIFELINE CURVE 94
FIGURE 35 EUROPE DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2022 103
FIGURE 36 EUROPE DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2023-2030 (USD MILLION) 104
FIGURE 37 EUROPE DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, CAGR (2023-2030) 104
FIGURE 38 EUROPE DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, LIFELINE CURVE 105
FIGURE 39 EUROPE DRUG MODELING SOFTWARE MARKET: BY END USER, 2022 110
FIGURE 40 EUROPE DRUG MODELING SOFTWARE MARKET: BY END USER, 2023-2030 (USD MILLION) 111
FIGURE 41 EUROPE DRUG MODELING SOFTWARE MARKET: BY END USER, CAGR (2023-2030) 111
FIGURE 42 EUROPE DRUG MODELING SOFTWARE MARKET: BY END USER, LIFELINE CURVE 112
FIGURE 43 EUROPE DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 122
FIGURE 44 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 124
FIGURE 45 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 124
FIGURE 46 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 125
FIGURE 47 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 125
FIGURE 48 EUROPE DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 208